DXCMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
DEXCOM INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$85.98−0.06 (-0.07%)
Close on Oct 19, 2026
- Market cap
- $33.54B
- P/E (TTM)
- 34.1
- Dividend yield
- –
Share price
+$19.38 (+29.10%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
DEXCOM INC grew revenue 15.5% to $4.97B over the twelve months to Jun 30, 2026. Operating income rose 65.8% to $1.14B, moving the operating margin from 16.0% to 22.9%. Free cash flow was $1.41B, up 146.1% from a year earlier.
Revenue
$4.97B
+15.5% vs. a year earlier
Operating income
$1.14B
+65.8% vs. a year earlier
Free cash flow
$1.41B
+146.1% vs. a year earlier
EPS, diluted
$2.52
+76.2% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $33.54B
- P/E ratio
- 34.1
- Price to sales
- 6.75
- Price to book
- 12.79
- Dividend yield
- –
- Free cash flow yield
- 4.19%
Fundamentals
- Revenue
- $4.97B
- Net income
- $999.70M
- EPS, diluted
- $2.52
- Free cash flow
- $1.41B
- Book value per share
- $6.72
- Diluted shares
- 390M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$4.97B+15.5% YoY
Gross profit
$3.10B+22.8% YoY
Operating income
$1.14B+65.8% YoY
Net income
$999.70M+74.9% YoY
EPS, diluted
$2.52+76.2% YoY
Free cash flow
$1.41B+146.1% YoY
Reported periodTrailing twelve months